A Novel IgG–IgM Autoantibody Panel Enhances Detection of Early-stage Lung Adenocarcinoma from Benign Nodules
Open Access
- 11 December 2024
- journal article
- Published by Oxford University Press (OUP) in Genomics, Proteomics & Bioinformatics
- Vol. 22 (6)
Abstract
Autoantibodies hold promise for diagnosing lung cancer. However, their effectiveness in early-stage detection needs improvement. In this study, we investigated novel IgG and IgM autoantibodies for detecting early-stage lung adenocarcinoma (Early-LUAD) by employing a multi-step approach, including Human Proteome Microarray (HuProtTM) discovery, focused microarray verification, and ELISA validation, on 1246 individuals consisting of 634 patients with Early-LUAD (stage 0–I), 280 patients with benign lung disease (BLD), and 332 normal healthy controls (NHCs). HuProtTM selected 417 IgG/IgM candidates, and focused microarray further verified 55 significantly elevated IgG/IgM autoantibodies targeting 32 tumor-associated antigens in Early-LUAD compared to BLD/NHC/BLD+NHC. A novel panel of 10 autoantibodies (ELAVL4-IgM, GDA-IgM, GIMAP4-IgM, GIMAP4-IgG, MGMT-IgM, UCHL1-IgM, DCTPP1-IgM, KCMF1-IgM, UCHL1-IgG, and WWP2-IgM) demonstrated a sensitivity of 70.5% and a specificity of 77.0% or 80.0% for distinguishing Early-LUAD from BLD or NHC in ELISA validation. Positive predictive values for distinguishing Early-LUAD from BLD with nodules ≤ 8 mm, 9–20 mm, and > 20 mm significantly increased from 47.27%, 52.00%, and 62.90% [low-dose computed tomography (LDCT) alone] to 79.17%, 71.13%, and 87.88% (10-autoantibody panel combined with LDCT), respectively. The combined risk score (CRS), based on the 10-autoantibody panel, sex, and imaging maximum diameter, effectively stratified the risk for Early-LUAD. Individuals with 10 ≤ CRS ≤ 25 and CRS > 25 indicated a higher risk of Early-LUAD compared to the reference (CRS < 10), with adjusted odds ratios of 5.28 [95% confidence interval (CI): 3.18–8.76] and 9.05 (95% CI: 5.40–15.15), respectively. This novel panel of IgG and IgM autoantibodies offers a complementary approach to LDCT in distinguishing Early-LUAD from benign nodules.Keywords
This publication has 64 references indexed in Scilit:
- Clinical validation of an autoantibody test for lung cancerAnnals of Oncology, 2010
- Development of Autoantibody Signatures as Novel Diagnostic Biomarkers of Non–Small Cell Lung CancerClinical Cancer Research, 2010
- Profiling the Human Protein-DNA Interactome Reveals ERK2 as a Transcriptional Repressor of Interferon SignalingCell, 2009
- Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cellsJournal of Clinical Investigation, 2009
- Dysregulation of GIMAP genes in non-small cell lung cancerLung Cancer, 2008
- Gimap4 accelerates T-cell deathBlood, 2006
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaNew England Journal of Medicine, 2005
- FIGC, a novel FGF‐induced ubiquitin‐protein ligase in gastric cancersFEBS Letters, 2004
- Presentation of multivariate data for clinical use: The Framingham Study risk score functionsStatistics in Medicine, 2004
- Natural IgM antibodies and immunosurveillance mechanisms against epithelial cancer cells in humans.2003